AMGEN INC

AMGN Nasdaq CIK: 0000318154

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
Mailing Address ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
Phone (805)447-1000
Fiscal Year End 1231
EIN 953540776

Financial Overview

FY2025

$11.97B
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC
4 Insider stock transaction report March 18, 2026 View on SEC

Annual Reports

10-K February 13, 2026
  • Amgen delivered a robust performance in 2025 with significant financial gains, including 10.4% revenue growth and 15.8% net income growth.
  • The successful integration of Horizon Therapeutics contributed $4.0 billion to total revenue, alongside strong organic growth from established products.
View Analysis

Insider Trading

STRONG SELL 2 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.